Perrigo Company plc heads into the August earnings period with one of the heaviest short positions in the pharmaceutical sector, yet the past two weeks have seen a meaningful retreat in bearish conviction.
Short interest is the central tension here. At 15.6% of the free float, the short position remains large in absolute terms — but it has fallen roughly 11% from its mid-July peak of around 17.9% of float. That drift lower has been steady: from ~24.9 million shares borrowed on July 10 down to 21.5 million by August 4. The ORTEX short score tells a similar story — it peaked near 69.4 on July 24 and has since eased to 65.5, a move that suggests short-side momentum is fading without shorts capitulating entirely. Borrow conditions remain relaxed, offering no squeeze pressure: the cost to borrow is just 0.51%, and availability is generous at 310%, well above the 52-week floor of 146%. With that much room in the lending pool, new shorts face no friction entering positions.
Options positioning is calmer than the short interest level might imply. The put/call ratio is 0.45, only fractionally above its 20-day average of 0.42, and the z-score of under 1.0 shows no unusual hedging demand. That's a notable contrast — a stock with 15%-plus short interest typically sees more pronounced put activity. The relative absence of defensive options positioning suggests the pressure on the stock has been driven more by outright short selling than by institutional hedging.
The Street's view of Perrigo has been consistently cautious for several months. The most recent analyst data flags repeated target-price cuts through late 2025 and early 2026, with JP Morgan downgrading from Overweight to Neutral in November 2025 and trimming again to $18 in December. Canaccord maintained its Buy but halved its target to $20 in November, then cut again to $17 in February. These figures are now several months stale, so the precise numbers carry less weight — but the direction of travel is clear: the Street has repeatedly reset expectations lower. The consensus target of $16.50 against a current price of $10.78 implies significant distance to fair value by analyst estimates, though the multiple compression visible in valuation data tells a different story. The price-to-book is below 0.5 and the PE ratio is just 4.5. The dividend score ranks in the 98th percentile of the universe, yet the last actual dividend payment on record was 2022 — that score likely reflects historical yield metrics rather than a current payout.
Institutional ownership adds an interesting wrinkle. BlackRock added 3.9 million shares in Q2, lifting its stake to 15.2% of the company. That's a material increase from a passive behemoth — it doesn't signal a strategic view, but it does represent a significant supply absorption at current prices. T. Rowe Price holds a further 10.8%, unchanged. Against that backdrop, the 15.6% short interest is running neck-and-neck with BlackRock's stake alone, a configuration that bears watching if short covering accelerates.
On the peer tape this week, BHC was the outlier — up 42% on the week before giving back 8% on Tuesday, a move that dwarfed anything in the PRGO neighborhood. AMPH slipped 1.2% over the same period while HROW added 1.3%, leaving PRGO's 4.7% weekly gain looking constructive relative to its closer-correlated peers.
The key variable to track is whether the slow-burn short cover continues, or whether the stock needs a fundamental catalyst — most likely earnings guidance — to reset the remaining bearish positioning.
See the live data behind this article on ORTEX.
Open PRGO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
